Table 5.
Univariate and multivariate Cox regression analyses of SLC2A3 expression and the clinicopathological factors in the validation set (GSE39582)
| Overall survival | Disease-free survival | |||
|---|---|---|---|---|
| HR(95% CI of HR) | P valuea | HR(95% CI of HR) | P valuea | |
| SLC2A3 low | 1.00 (Reference) | 1.00 (Reference) | ||
| UVA SLC2A3 high | 1.57 (1.16–2.12) | 0.004 | 1.46 (1.06–2.01) | 0.021 |
| MVA SLC2A3 high | 1.50 (1.11–2.03) | 0.009 | 1.38 (1.00–1.91) | 0.048 |
| Age < = 65 | 1.00 (Reference) | |||
| Age > 65 | 1.39 (1.01–1.91) | 0.043 | ||
| AJCC stage I, II | 1.00 (Reference) | 1.00 (Reference) | ||
| AJCC stage III, IV | 1.82 (1.34–2.46) | < 0.001 | 2.84 (2.03–3.98) | < 0.001 |
Abbreviations: HR hazard ratio, CI confidence interval, UVA univariate; MVA,multivariate
aCalculated using the Wald test